Stacks Image 365
Aging-associated neurodegenerative diseases represent an enormous disease burden

Only treatments alleviating symptoms are available for the most common neurodegenerative diseases. Better understanding of etiology and mechanisms is needed to accelerate development of novel therapies.
Stacks Image 345
Misfolding and aggregation of specific proteins is a hallmark of many neurodegenerative diseases

Synapses and neurons are particularly sensitive to proteostatic stress and loss of connectivity may be initiated by misfolded proteins. Understanding the regulation of these proteins on the molecular level is critical for developing novel therapies.
Protein interaction networks form the foundation of cellular functionality

We use protein-fragment complementation assay (PCA) technology to study protein-protein interaction dynamics in live cells. Our focus in on pathways that play a key role in Alzheimer's disease.
Stacks Image 359
Microfluidic technologies are changing the way neuronal connectivity can be studied in vitro

We use engineered microstructures for high-precision control of neuronal connectivity allowing new approaches for studying axonal and synaptic biology.
Stacks Image 361
Laboratory of Dr. Henri Huttunen studies molecular mechanisms of neurodegenerative diseases such as Alzheimer's disease. We are particularly focusing on pathogenic events occurring in the degenerating neurons and interactions between key proteins that may be responsible for initiation and progression of neurodegeneration on the cellular level. We have developed various technologies to facilitate cellular and molecular studies of neurons and their molecular constituents. Our goal is to accelerate development of therapeutics for neurodegenerative diseases by associating disease risk genes to cellular pathways and discovering new mechanisms and therapeutic targets. We are located at the Neuroscience Center, University of Helsinki.